EastGate Biotech Patent Portfolio Update:
SALT LAKE CITY and TORONTO, February 3, 2015 (PRNewswire/-) EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules provides update on its patent portfolio for its sub-micron self-nanoemulsifying platform technology.
The company recently expanded its new pharmaceutical product development to include large molecules as active compounds that will address indications in diabetes, obesity and the overall metabolic syndrome. In order to protect our innovation and know-how the company had filed these initial provisional patents:
US 61/947,678 Title: Pharmaceutical Composition for Transmucosal Delivery
US 61/947,698 Title: Treatment of Diabetes and Metabolic Syndrome
These two provisional patents relate specifically to the company’s intraoral insulin formulation. The company has outlined its sub-micron self-nanoemulsifying platform technology to develop alternative dosage forms for delivery of known biologically active molecules. These technological approaches have demonstrated robustness and resulted in diversification of drug delivery products. As a result, the company was able to develop an intraoral insulin tablet that is delivered to the mouth for intraoral insulin absorption (not GI-tract delivery).
The company will continue to prepare additional patent application filings in order to bolster the intellectual property and know-how of the intraoral insulin tablet and its other dosage forms.
The company already has patents for its intraoral Lorazepam Spray for acute seizures:
PCT/C2014/000126 Title: Pharmaceutical Composition for Transmucosal Administration of Benzodiazepines
PCT/CA2014/000127 Title: Pharmaceutical Composition For Enhanced Transmucosal Administration of Benzodiazepines
The company plans on expanding the patent portfolio for this indication as the clinical and scale-up manufacturing development continues.
“We are pleased with the expansiveness of our patent portfolio for our pharmaceutical products”, says Anna Gluskin, CEO of EastGate Biotech Corp. “The company’s intent is to commercially-realize our unique sub-micron self-nanoemusifying delivery system and the breadth of the Intellectual Property will open the doors to licensing partners interested in innovative drugs in the highly diverse marketplace”, continues Gluskin.
Cautionary statement on forward-looking information
All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, including the provisions for “safe harbour” under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.
The words “anticipates”, “plans”, “expects”, “indicate”, “intend”, “scheduled”, “estimates”, “forecasts”, “focus”, “guidance”, “initiative”, “model”, “methodology”, “outlook”, “potential”, “projected”, “pursue”, “strategy”, “study”, “targets”, or “believes”, or variations of or similar such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, or “should”, “might”, or “way forward”, “will be taken”, “will occur” or “will be achieved” and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Rose Perri 1-647-692-0652